Enzolytics, Inc. (OTCMKTS:ENZC – Get Free Report) saw a large decline in short interest during the month of May. As of May 29th, there was short interest totaling 209 shares, a decline of 78.5% from the May 14th total of 972 shares. Based on an average trading volume of 10,580,690 shares, the short-interest ratio is presently 0.0 days.
Enzolytics Price Performance
Shares of OTCMKTS ENZC traded down $0.00 during midday trading on Thursday, reaching $0.00. 10,529,947 shares of the stock were exchanged, compared to its average volume of 10,436,679. Enzolytics has a 12 month low of $0.00 and a 12 month high of $0.00.
Enzolytics Company Profile
Enzolytics, Inc is a clinical-stage biotechnology company focused on advancing immunotherapeutic treatments for infectious diseases. Its core platform employs proprietary peptide and monoclonal antibody technologies designed to target and neutralize viral pathogens. The company’s lead candidate, Investigator Therapeutic Vaccine-1 (ITV-1), is a 72-amino-acid peptide engineered to bind multiple HIV-1 strains and support immune response in affected individuals.
In addition to its HIV program, Enzolytics has leveraged its antibody discovery engine to develop broadly neutralizing monoclonal antibodies against coronaviruses, including SARS-CoV-2.
Featured Stories
- Five stocks we like better than Enzolytics
- Microsoft Just Gave Investors 3 Dates They Can’t Afford to Ignore
- NVIDIA’s Outlook Gains Momentum: Stock Price to Follow
- The World Cup Is Coming—These 3 Stocks Could Cash In
- Spotify’s “North Star” Outlook Was Music to Investors Ears
Receive News & Ratings for Enzolytics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzolytics and related companies with MarketBeat.com's FREE daily email newsletter.
